Abacus Medicine

Abacus Medicine's reported carbon emissions

In 2025, Abacus Medicine, headquartered in Denmark (DK), reported total carbon emissions of approximately 1,090,451,900 kg CO2e. This figure encompasses emissions across all scopes, including Scope 1 emissions of 317,700 kg CO2e, Scope 2 emissions of 413,200 kg CO2e (market-based), and a significant Scope 3 contribution of approximately 1,090,045,900 kg CO2e. The company has shown a commitment to transparency in its emissions reporting, with data cascaded from its parent company, Abacus Medicine A/S. However, there are currently no specific reduction targets or initiatives outlined in their sustainability strategy, as indicated by the absence of documented reduction targets or climate pledges. Over the past few years, Abacus Medicine's emissions have fluctuated, with 2024 emissions recorded at approximately 832,380,000 kg CO2e and 2023 emissions at approximately 859,500 kg CO2e (Scope 1 and 2 combined). The company continues to focus on understanding and managing its carbon footprint, particularly in the context of its supply chain and operational activities. As a current subsidiary of Abacus Medicine A/S, the company is positioned to align with broader corporate sustainability goals, although specific initiatives and targets remain to be established.